BioAge Posts Wider Q3 Loss as BGE-102 Trials Advance; QUELL-CV Data Due Q4
BIOA is trading near its 52-week low of $4.81 (14% above the low).
Summary
BioAge reported a Q3 2026 net loss of $33.5 million, or $0.73 per share, versus $20.2 million ($0.56) a year earlier, driven by R&D spending that jumped to $30.2 million from $18.5 million on BGE-102 trial costs and manufacturing. Collaboration revenue fell to $0.3 million from $2.1 million, largely due to a $1.7 million cumulative catch-up adjustment tied to the September 2026 Novartis amendment. The balance sheet is the key offset: $352.3 million in cash and securities, which management says funds operations through 2029. The near-term driver is QUELL-CV, the Phase 2 dose-ranging study of oral BGE-102 in obesity with elevated inflammation, now fully enrolled at roughly 160 participants, with topline data expected in Q4 2026. QUELL-DME, the Phase 2 diabetic macular edema trial dosed in September, reads out in the second half of 2027, and an APJ agonist IND is targeted by year-end 2026.
At the time of this announcement, BIOA was trading at $5.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $254.3M. The 52-week trading range was $4.81 to $25.96. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.